Shanghai Fosun Pharmaceutical (600196) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600196 Shanghai Fosun Pharmaceutical

Watchlist

25.51
+0.29+1.15%

Market Closed Dec 27 15:00 CST

68.15BMarket Cap32.25P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
Gelonghui FinanceDec 27 04:50 ET
On December 27, FOSUN PHARMA (02196.HK) spent 2.8723 million Hong Kong dollars to repurchase 0.2045 million shares.
On December 27, Gelonghui reported that FOSUN PHARMA (02196.HK) announced the repurchase of 0.2045 million shares for HKD 2.8723 million on December 27, 2024, with a repurchase price of HKD 13.94-14.1 per share.
Gelonghui FinanceDec 27 04:41 ET
Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal
MT NewswiresDec 20 03:28 ET
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
cls.cnDec 19 09:27 ET
FOSUN PHARMA (600196.SH) has signed a cooperation and licensing agreement with Palleon, intending to carry out joint clinical research on the licensed product Hanlikang.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary HENLIUS signed an agreement with Palleon...
Zhitong FinanceDec 19 05:27 ET
FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.
Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.
Gelonghui FinanceDec 19 05:11 ET

Comments

Spinee

Jun 24 21:45

HSI Opens Up 60 pts; LI AUTO & NIO Advance, as HENLIUS Rockets 21%

Hong Kong stocks opened higher in the morning. $Hang Seng Index (800000.HK)$opened 60 points or 0.3% higher at 18,088. $Hang Seng China Enterprises Index (800100.HK)$ opened 22 points or 0.3% higher at 6,463. $Hang Seng TECH Index (800700.HK)$ opened 11 points or 0.3% higher at 3,689.
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...

Spinee

Apr 25, 2023 11:34

HSI Slides 342 Pts; Techs & Pharmas Gloom

$Hang Seng Index (800000.HK)$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index (800100.HK)$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index (800700.HK)$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-W (09988.HK)$ dived 3.2% to $84.1.
$TENCENT (00700.HK)$ sank 1.9% to $338.4.
$MEITUAN-W (03690.HK)$ , $XIAOMI-W (01810.HK)$ , ...

Senorita Earnings

Mar 1, 2023 23:54

Columns Expert Meeting Minutes | Seven Development Trends of the China Medical Aesthetics Industry

Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...

Spinee

Dec 14, 2022 00:12

The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $FOSUN PHARMA (02196.HK)$ shares were opened 12% higher to 29 yuan.
$Pfizer (PFE.US)$ $AIM VACCINE (06660.HK)$

Spinee

Dec 6, 2022 21:36

In terms of allocation of Chinese stocks, it is suggested to focus on three main lines:

First, under the optimization of epidemic prevention, the repair market of damaged plates in the early stage, such as biomedical, aviation, wine travel and other plates;
Second, under the demand of stable growth, the industry policy margin is loose, such as the real estate industry chain and the Internet and other industries;
Third, under the theme of security for a long time, energy security, self contro...